David Sidransky - Ayala Pharmaceuticals Independent Director
| ADXSDelisted Stock | USD 0.62 0.03 4.62% |
Director
Dr. David Sidransky, M.D., is Independent chairman of the Board of the Company. He is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky was the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a director and ViceChairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and Ayala and serves on the Board of Directors of Galmed and Orgenesis. He has served on scientific advisory boards of MedImmune, Roche, Amgen, and Veridex, LLC, among others. Dr. Sidransky served as Director of the American Association for Cancer Research . since 2015.
| Age | 57 |
| Tenure | 9 years |
| Phone | 609 452-9813 |
| Web | www.ayalapharma.com |
David Sidransky Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Sidransky against Ayala Pharmaceuticals otc stock is an integral part of due diligence when investing in Ayala Pharmaceuticals. David Sidransky insider activity provides valuable insight into whether Ayala Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Ayala Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ayala Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Sidransky over three weeks ago Acquisition by David Sidransky of tradable shares of Orgenesis at 5.42 subject to Rule 16b-3 | ||
David Sidransky over three months ago Acquisition by David Sidransky of 15495 shares of Champions Oncology subject to Rule 16b-3 | ||
David Sidransky over six months ago Acquisition by David Sidransky of 11480 shares of Champions Oncology subject to Rule 16b-3 |
Ayala Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (24.13) % which means that it has lost $24.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.98) %, meaning that it created substantial loss on money invested by shareholders. Ayala Pharmaceuticals' management efficiency ratios could be used to measure how well Ayala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 19 K in liabilities. Ayala Pharmaceuticals has a current ratio of 15.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ayala Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Ayala Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ayala Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ayala to invest in growth at high rates of return. When we think about Ayala Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Donald Olds | Acasti Pharma | 57 | |
| Jose Dorais | Aeterna Zentaris | N/A | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| Juergen Ernst | Aeterna Zentaris | 77 | |
| Carolyn Egbert | Aeterna Zentaris | N/A | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Kenneth Newport | Aeterna Zentaris | 48 | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| Gerard Limoges | Aeterna Zentaris | 74 | |
| Pierre Lapalme | Aeterna Zentaris | 75 | |
| Jean Belanger | Acasti Pharma | N/A | |
| Valier Boivin | Acasti Pharma | N/A | |
| Pierre Fitzgibbon | Acasti Pharma | 60 | |
| Michael Cardiff | Aeterna Zentaris | N/A | |
| Marcel Aubut | Aeterna Zentaris | N/A | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Reed Tuckson | Acasti Pharma | 63 | |
| JeanDaniel Belanger | Acasti Pharma | N/A | |
Management Performance
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 |
Ayala Pharmaceuticals Leadership Team
Elected by the shareholders, the Ayala Pharmaceuticals' board of directors comprises two types of representatives: Ayala Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ayala. The board's role is to monitor Ayala Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ayala Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ayala Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Independent Director | ||
| Mayo Pujols, VP of Manufacturing | ||
| Anthony Lombardo, Interim CEO | ||
| Richard Schwalm, Independent Director | ||
| Kenneth Berlin, President CEO, Director | ||
| Roni Appel, Independent Director | ||
| Richard Berman, Independent Director | ||
| Samir Khleif, Director | ||
| Ranya Dajani, Vice President Business Development | ||
| James Patton, Non-Executive Independent Chairman of the Board | ||
| Sara Bonstein, CFO and Sr. VP | ||
| Thomas McKearn, Independent Director | ||
| Tom Ridge, Director | ||
| Christopher Duke, COO, Senior Vice President | ||
| Robert Petit, Chief Scientific Officer and Executive VP | ||
| Molly Henderson, CFO, Executive Vice President | ||
| Daniel OConnor, President CEO, Director | ||
| David Mauro, Executive Vice President Chief Medical Officer | ||
| Gregory Mayes, COO, Executive Vice President |
Ayala Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Ayala Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ayala Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ayala Pharmaceuticals' short interest history, or implied volatility extrapolated from Ayala Pharmaceuticals options trading.
Pair Trading with Ayala Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ayala Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ayala Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Ayala OTC Stock
| 0.74 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
Moving against Ayala OTC Stock
| 0.84 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.82 | YS | YS Biopharma | PairCorr |
| 0.8 | VERU | Veru Inc Financial Report 9th of May 2024 | PairCorr |
| 0.78 | DOMH | Dominari Holdings | PairCorr |
| 0.49 | VCEL | Vericel Corp Ord Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Ayala Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ayala Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ayala Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ayala Pharmaceuticals to buy it.
The correlation of Ayala Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ayala Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ayala Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ayala Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |